Kura Oncology (KURA) Long-Term Debt Repayments (2018 - 2021)

Kura Oncology's (KURA) quarterly Long-Term Debt Repayments came in at $6.5 million in Q2 2021, up 766.67% on a QoQ basis from $750000.0 in Q1 2021.

Kura Oncology (KURA) Long-Term Debt Repayments (2018 - 2021) Analysis & Trends

Kura Oncology (KURA) has 2 years of Long-Term Debt Repayments data on file, last reported at $6.5 million in Q2 2021.

On a quarterly basis, Long-Term Debt Repayments changed N/A year-over-year to $6.5 million in Q2 2021; TTM through Dec 2021 was $7.2 million, a N/A change from a year earlier, with the FY2021 full-year figure at $7.2 million, up 2800.0% from the prior year.
Long-Term Debt Repayments for Q2 2021 stood at $6.5 million, up from $750000.0 in the prior quarter.
Over the last five years, Long-Term Debt Repayments for KURA reached as high as $6.5 million in Q2 2021 and fell as low as $250000.0 in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	7.64 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Kura Oncology	925.97 Mn	925.97 Mn	18.00 Mn	-

Download Data